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washed with ethyl acetate (5 x). The aqueous phase was evaporated under reduced pressure using a rotary evaporator, redissolved in water, subjected to preparative reversed phase HPLC and desalted, giving the title compound. Yield (Purity): 10 .8 µmol, 47 % (> 99% HPLC). HPLC: (Gradient, 21% then 24% MeCN, 50 mM NaH 2 PO 4 buffer, pH 6.8). UV-VIS: λ max = 275 nm (pH 7), ε = 24660 (est.). 1 Using the procedure described for compound 2, 8-Carboxymethylthio-βphenyl-1, N²-ethenoguanosine-3', 5'-cyclic monophosphate (8-CMT-PET-cGMP, triethyl ammonium salt, 22 mg, 36 µmol) (see supplementary information) was reacted with NH 2 -PEG n -(CH 2 ) 2 NH 2 (2000 Da, polydispers). More PyBOP (0.5 eq) was added stepwise to drive the reaction to completion and yield the title compound. Yield (Purity): 35% (> 99% HPLC). HPLC: (28% MeCN, 25 mM NaH 2 PO 4 buffer, pH 6.8).
UV-VIS: λ max = 272 nm (pH 7), ε = 72000 (est. As confirmed by COSY NMR, the ribose H2' shows the same chemical shift as the solvent residual signal (4.80 ppm). 13 Cells were kept at 37°C in a humidified atmosphere of 5% CO 2 and subcultured every 2-3 days. For treatment, cells were plated in 24-well or 96-well plates, depending on the experiment, and after 8 h the medium was changed to serum-free medium. After additional 12 h (HCT 116) or 36 h (Caco-2 and HT-29), the cells were incubated in serum-free medium containing the test compounds at different concentrations for 24 h.
RNA Interference (RNAi)
A sequence beginning with an AA dinucleotide was chosen in the PKG2 mRNA, and we designed hairpin RNAi template oligonucleotides (shRNA). The control shRNA was generated from a scrambled sequence not targeting any known gene. The sequences (5'3') are as following: PKG2 AAGTGGAATACTATGACAAAG, scrambled GCATACTACCACTAGAGTTTA.
Retroviruses from pSUPER.retro.puro vector (OligoEngine, Seattle, WA, USA), expressing the shRNAs, were prepared by transient transfection in amphotropic Phoenix-AMPHO packaging cells (ATCC, Rockville, MD, USA). Caco-2 cells were infected with either shRNA or scramble expressing retroviruses and selected with puromycin (1 µg/ml). The acquired stable clones were called Caco-2 shRNA PKG2 and Caco-2 scrambled and the effect on PKG2 expression was assessed by immunoblotting using an anti-PKG2 antibody.
Western Blot analysis
For protein extraction, cells were harvested at 70-90% confluence, pelleted and resuspended in RIPA lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM activation inhibited growth in all tested colon cancer cell lines possibly by interfering with β-catenin activation but it is possible that additional mechanism(s) are activated by PKG2 [32] . One of these pathways may involve VASP phosphorylation at Serine 239 that we demonstrated after treatment with the compounds. In fact, a direct correlation of VASP phosphorylation with colon cancer viability was recently reported [13] . Another mechanism might be linked to the activation of tumor suppressors of the FoxO family as previously found in different colon cancer cell lines [33] - [35] .
The effects of compound 2 on Caco-2 cell viability is mediated by PKG2
To assess the role of PKG2 in the decrease of cell viability after treatment with cGMP analogues, we downregulated PKG2 expression using shRNA targeting PKG2 mRNA in Caco-2 cells. As shown in Fig. 8A , expression of PKG2 was reduced to around 18% compared to the endogenous expression in Caco-2 or in Caco-2 scrambled cells (negative control, see methods). Downregulated cells were then treated with compound 2 at concentrations from 1 nM to 10 µM and cell viability was assessed using the MTT assay. Caco-2 and Caco-2 scrambled showed a similar reduction in cell viability after treatment (Fig. 8B) , whereas the effect of compound 2 was lost in Caco-2 shRNA PKG2 cells, suggesting that PKG2 plays an important role in the observed reduction in cell viability after treatment with compound 2.
Conclusions
This study presents three novel cGMP analogues, in the form of dimers with PEG linkers, and their effects in three colorectal cancer cell lines. We report that treatment with different cGMP analogues led to a significant reduction of cell viability. In the Caco-2 and HCT 116 cell lines the dimeric compound 2 generated the best result, in the HT-29 cell line the best result was obtained with compound 1. In all cases the results with these dimeric compounds were more pronounced than with the monomeric 8-Br-PET-cGMP. The results from the Ethidium Homodimer and BrdU assays suggested that the reduction in cell viability was mainly due to reduced proliferation and a cytotoxic effect was observed only with compound 1 in HT-29 cells. Downregulation of PKG2 in the Caco-2 cell line abolished the effect of compound 2, strongly suggesting that the reduction of cell viability was mediated by PKG2 activity.
Taken together these results suggest that activation of PKG2 could be a therapeutic target in the treatment of colon cancer by reducing proliferation. Most importantly, dimeric cGMP analogues are cell permeable and can improve the beneficial effects that have been observed using monomeric cGMP analogues. 
